Cees A. Schumacher
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.
Journal: Frontiers in physiology
Published: March 03, 2023
Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 29, 2021
Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.
Journal: Cardiovascular research
Published: December 18, 2020
Structurally Abnormal Myocardium Underlies Ventricular Fibrillation Storms in a Patient Diagnosed With the Early Repolarization Pattern.
Journal: JACC. Clinical electrophysiology
Published: April 09, 2020
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Journal: Cardiovascular research
Published: December 12, 2018
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
Journal: Frontiers in physiology
Published: July 31, 2018
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Journal: Diabetologia
Published: October 05, 2017
Reducing mitochondrial bound hexokinase II mediates transition from non-injurious into injurious ischemia/reperfusion of the intact heart.
Journal: Journal of physiology and biochemistry
Published: July 25, 2016
In vivo mouse myocardial (31)P MRS using three-dimensional image-selected in vivo spectroscopy (3D ISIS): technical considerations and biochemical validations.
Journal: NMR in biomedicine
Published: May 17, 2015
Last Updated: 09/26/2026